Summary of publication
This report presents the findings of an independent evaluation of the Australia’s investments in Product Development Partnerships since 2013. The evaluation examined Australia’s funding to three PDPS, namely, the Foundation for Innovative Diagnostics (FIND), the Medicines for Malaria Venture (MMV) and the TB Alliance. The evaluation found that collectively, PDPs had delivered five products, including two TB diagnostics, one TB medicine and two malaria medicines were successfully trialled new or modified product registered for patients’ use in the Asia Pacific during the investment period, which surpassed the design outcome of two products successfully trialled new or modified product registered. The report concludes that investment in PDPs represents good value for money for DFAT. Recommendations as well as options for future funding to PDPs are provided in the report.